Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Phase 3 Trials Regulatory Approval FDA Regulations Market Competition Oncology Eli Lilly Phase II Trials Patient Outcomes Obesity Treatments Cancer Therapies Preclinical Research GLP-1 Drugs Patient Safety Efficacy Studies Treatment Options RNA Therapeutics Diagnostics Lung Cancer Treatment AGAMREE Obesity Treatment Metabolic Diseases Market Risks Efruxifermin Phase 1/2 Trials Pharmacokinetics Efficacy Orforglipron Injectable Drugs Late-Stage Testing Influenza Treatment Drug Pipeline Food Allergy Treatments Phase I/II Trials Pipeline Management Psychedelic Research Cancer Treatments Efficacy and Safety Market Analysis Cancer Drugs Investigational Drugs Prescription Medications Phase 1 Trials Investigational New Drugs Pediatric Programs Market Expectations Targeted Therapies Phase 3 Studies Semaglutide FDA Approval Process Ampreloxetine Retatrutide Experimental Drugs Phase Ib/IIa Trials Next-Generation Treatments Precision Therapy Regulatory Compliance Merck Oncology Pipeline

Merck Beats Q3 Estimates as Keytruda QLEX Fuels Strong Sales

Strong quarter underpins Merck's push to protect Keytruda revenue ahead of 2028 patent expirations.

Jazz Pharmaceuticals to Buy Actio Biosciences for $820 Million

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Zymeworks to Buy Theravance for $929 Million

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Lilly Wins Exclusive License to Ascidian RNA Exon-Editing Platform for Kidney Diseases

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

SIGA Expects $13 Million TPOXX Delivery in Q2 After Quiet Start to 2026

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Regeneron and Telix Form 50/50 Partnership to Develop Targeted Radiopharmaceuticals

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years